| colorectalLongi {frailtypack} | R Documentation |
Follow-up of metastatic colorectal cancer patients : longitudinal measurements of tumor size
Description
Randomly chosen 150 patients from the follow-up of the FFCD 2000-05 multicenter phase III clinical trial originally including 410 patients with metastatic colorectal cancer randomized into two therapeutic strategies: combination and sequential. The dataset contains measurements of tumor size (left-censored sums of the longest diameters of target lesions; transformed using Box-Cox) with baseline characteristics(treatment arm, age, WHO performance status and previous resection).
Usage
data(colorectalLongi)
Format
This data frame contains the following columns:
- id
identification of each subject. Repeated for each recurrence
- year
time of visit counted in years from baseline
- tumor.size
Individual longitudinal measurement of transformed (Box-Cox with parameter 0.3) sums of the longest diameters, left-censored due to a detection limit (threshold
s=-3.33).- treatment
To which treatment arm a patient was allocated? 1: sequential (S); 2: combination (C)
- age
Age at baseline: 1: <50 years, 2: 50-69 years, 3: >69 years
- who.PS
WHO performance status at baseline: 1: status 0, 2: status 1, 3: status 2
- prev.resection
Previous resection of the primate tumor? 0: No, 1: Yes
Note
We thank the Federation Francophone de Cancerologie Digestive and Gustave Roussy for sharing the data of the FFCD 2000-05 trial supported by an unrestricted Grant from Sanofi.
References
Ducreux, M., Malka, D., Mendiboure, J., Etienne, P.-L., Texereau, P., Auby, D., Rougier, P., Gasmi, M., Castaing, M., Abbas, M., Michel, P., Gargot, D., Azzedine, A., Lombard- Bohas, C., Geoffroy, P., Denis, B., Pignon, J.-P., Bedenne, L., and Bouche, O. (2011). Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. The Lancet Oncology 12, 1032-44.